August 27, 2014 5:08 PM ET

Healthcare Equipment and Supplies

Company Overview of Nordion (Canada) Inc.

Company Overview

Nordion (Canada) Inc. provides medical isotopes, radiotherapeutics, and related technologies for molecular imaging. It offers molecular medicine products, including oncology, cardiology, neurology, and research products; molecular medicine services, such as discovery and pre-clinical, clinical and commercialization, and molecular imaging services; and sterilization technologies, including irradiators, and training and education services. The company serves hospitals and clinics; medical supply, biotechnology, and pharmaceutical companies; and food processors and manufacturers. Nordion (Canada) Inc. was formerly known as MDS Nordion, Inc. and changed its name to Nordion (Canada) Inc. in Novem...

447 March Road

Ottawa, ON K2K 1X8

Canada

Founded in 1946

Phone:

613-592-2790

Fax:

613-592-6937

Key Executives for Nordion (Canada) Inc.

Chief Executive Officer
Age: 61
Chief Financial Officer and Senior Vice-President
Vice President of Technology
Associate General Counsel and Secretary
Vice President of Communications
Compensation as of Fiscal Year 2014.

Nordion (Canada) Inc. Key Developments

Navidea Biopharmaceuticals, Inc. Signs Manufacturing and Supply Agreement with Nordion (Canada) Inc

Navidea Biopharmaceuticals Inc. announced that it has entered into an agreement with Nordion (Canada) Inc. to produce and supply (123) I-labeled NAV5001 for Navidea's late-phase clinical trials. The agreement focuses on Nordion's cGMP manufacturing and supply of NAV5001 clinical trial material to be produced at Nordion's Vancouver, British Columbia, facility. Accordingly, Nordion will radiolabel Navidea's precursor drug product with Iodine-123 to form [(123) I]NAV5001, manage the logistics and make arrangements for shipment of NAV5001 to third-party clinical trial sites on behalf of Navidea. The agreement may serve as a predecessor to a commercial supply arrangement in the future.

Lantheus Medical Imaging, Inc. Enters into Amendment No. 2 to the Molybdenum-99 Purchase & Supply Agreement with Nordion (Canada) Inc

On October 19, 2012, Lantheus Medical Imaging Inc. entered into Amendment No. 2, effective as of October 15, 2012, to the Molybdenum-99 Purchase & Supply Agreement, dated as of April 1, 2010, between the Lantheus Medical Imaging Inc. and Nordion (Canada) Inc. The Amendment extends the contract term of the Agreement from December 31, 2013 to December 31, 2015 and modifies the company's purchase requirements and supply fees. The Agreement allows for termination upon the occurrence of certain events, including, but not limited to, certain cost increases experienced by Nordion (but in such event not earlier than October 1, 2014), failure to comply with material obligations by either party, bankruptcy of either party or force majeure events.

Similar Private Companies By Industry

Company Name Region
E-Z-Em Canada, Inc. Americas
EastMed Inc. Americas
Independent Needs Centre Americas
Imagin Diagnostic Centres, Inc. Americas
BlueLight analytics inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nordion (Canada) Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.